Clinical trial
Proton Therapy and Bevacizumab for Primary Liver Tumors
NCT00426829 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00426829 |
|---|---|
| Title | Proton Therapy and Bevacizumab for Primary Liver Tumors |
| Official title | Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma |
| Intervention type | Drug, Radiation |
| Interventions | Bevacizumab, Proton Radiation Therapy |
| Enrollment | 3 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jan 25, 2007 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: